RA-2600 vendors competing

No vendor pricing available for this peptide yet.

Research details

RA-260 — research data

Half-life~4–6 hours. Daily dosing.
Regulatory statusNot FDA-approved
NCAA D1Banned

Overview

About RA-260

Mechanism of action

Research peptide listed alongside ARA-290 class; likely refers to a higher-dose formulation or related non-erythropoietic EPO-derived peptide; activates innate repair receptor (IRR); anti-inflammatory and tissue repair.

Safety profile

Limited specific data for RA-260 formulation. Assumed similar to ARA-290: injection site reactions, generally well-tolerated. · High-dose ARA-290 variant; limited data; parent compound (ARA-290) well-tolerated in trials

Related pages

More on RA-260

Failed to fetch